Invesco Ltd. Eiger Bio Pharmaceuticals, Inc. Transaction History

Invesco Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.89 - $2.52 $2,732 - $7,736	3,070 Added 21.25%	17,518 $15,000
Q4 2022 Feb 13, 2023	SELL	$1.02 - $7.48 $1,653 - $12,125	-1,621 Reduced 10.09%	14,448 $17,000
Q3 2022 Nov 14, 2022	BUY	$6.04 - $9.66 $12,128 - $19,397	2,008 Added 14.28%	16,069 $121,000
Q2 2022 Aug 15, 2022	BUY	$4.99 - $8.96 $70,164 - $125,986	14,061 New	14,061 $89,000
Q4 2021 Feb 14, 2022	SELL	$5.12 - $8.19 $58,680 - $93,865	-11,461 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$6.68 - $9.1 $9,064 - $12,348	1,357 Added 13.43%	11,461 $76,000
Q2 2021 Aug 17, 2021	BUY	$7.82 - $9.23 $79,013 - $93,259	10,104 New	10,104 $86,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.